



C ACC AGC AAC

→ Precore ATG CAA CTT TTT CAC CTC TGC CTA ATC ATC TCT TGT ACA TGT CCC ACT GTT CAA GCC TCC AAG CTG TGC CTT GGG TGG CTT TGG GGC ATG GAC ATT GAC CCT TAT AAA GAA TTT GGA GCT ACT GTG GAG TTA CTC TCG TTT TTG CCT TCT GAC TTC TTT CCT TCC GTC AGA GAT CTC CTA GAC ACC GCC TCA GCT CTG TAT CGG GAA GCC TTA GAG TCT CCT GAG CAT TGC TCA CCT CAC CAC ACC GCA CTC AGG CAA GCC ATT CTC TGC TGG GGG GAA TTG ATG ACT CTA GCT ACC TGG GTG GGT AAT AAT TTG GAA GAT CC G CAT CAA GGG ATC TAG TAG CCA GCA TCT AGG GAT CTA GTA GTC AAT TAT GTT AAT ACT AAC ATG GGT TTA AAA ATT AGG CAA CTA TTG TGG TTT CAT ATA TCT TGC CTT ACT TIT GGA AGA GAG ACT GTA CTT GAA TAT TTG GTA TCT TTC GGA GTG TGG ATT CGC ACT CCT CCA GCC TAT AGA CCA CCA AAT GCC CCT ATC TTA TCA ACA CTT CCG GAA ACT ACT GTT GTT AGA CGA CGG GAC CGA GGC AGG TCC CCT AGA AGA AGA ACT CCC TCG CCT CGC AGA CGC AGA TCT CCA TCG CCG CGT CGC AGA AGA TCT CAA TCT CGG GAA TCT CAA TGT TAG






FIG. 3




FIG. 4



	ELISA fo	or HBe		ELISA for HB core		
Sample	ng/ml*	Sample	ng/mi*	Sample	ng/ml**	
Supernatant	(Incstar)	Lysate	(Incstar)	Lysate	(Abbott)	
BC10ME	0.0	BC10ME	0.0	BC10ME	0	
BC/HBe 1-10	38.0	BC/HBe 1-10	24.8	BC core 6621	750	
BL/6	0.0	BL/6	0.0	BL/6	0	
BL/6/HBe 1-12	27.2	BL/6/HBe 1-12	26.0	BL/6 core 6625	100	
LMTK-	0.0	LMTK-	0.0	LMTK	0	
LM/HBe 1-3	24.8	LM/HBe 1-3	18.1	LM core 1-2	250	
EA2/K <sup>b</sup> EA2/K <sup>b</sup> /HBe 2-1	0.0 24.8			EA2/K <sup>b</sup> EA2/K <sup>b</sup> core 1-2	0 38	
JA2/K <sup>b</sup> JA2/K <sup>b</sup> /HBe 2-3	0.0 22.4			JA2/K <sup>b</sup> JA2/K <sup>b</sup> core 10-1	0 · 200	

Standard: rHBeAg (Biogen)
\*Standard: rHBcAg (Biogen)

FIG. 5



## IMMUNOPRECIPITATION/WESTERN BLOT




FIG. 6



Antibody Responses to HBcore

No. of I.M. Injections (2 sites)	lgG Titer to HBcore
2	640 160 2560 40 160
4	640 640 2560 640 640
6	2560 2560 2560 640 2560

FIG. 7





FIG. 8






FIG. 9





FIG. 10





**FIG. 11A** 




FIG. 11B



Ab Isotype Titers in C3H/He Mice Immunized with Formulated Vectors

n of lan	Cormulated			Anti-HBc/HBe	lc/HBe		
# 04 ills.   IM (2 sites)		lgG	61	62	G <sub>2b</sub>	G <sub>3</sub>	CIL
x2	Core 6A3	2560	40	10,240	40	0	+
9x	Core 6A3	2560	2560	10,240	160	0	+
×4	Precore/e5A	640	640	40	0	0	1

## FIG. 12







FIG. 13









FIG. 14B










FIG. 15B




FIG. 15C






FIG. 16A




FIG. 16B





FIG. 16C





Weeks from retrovector immunization